Recent Updates
Recently added Catalysts
MAZE Neutral Sentiment

SEPTEMBER 2024 I MAZE THERAPEUTICS

Key Takeaway: The article provides an overview of the privacy policy and cookie usage on the Maze Therapeutics website. It outlines the types of cookies used, including essential and third-party cookies, and explains their functions in enhancing user experience. The article also mentions the use of Google Analytics for collecting anonymous visitor data.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease

Full Press Release Details

• Privacy Overview
• Essential Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What types of cookies does Maze Therapeutics use?

Maze Therapeutics uses essential cookies and third-party cookies.

How does Maze Therapeutics use Google Analytics?

Google Analytics is used to collect anonymous visitor data for site improvement.

What is the purpose of essential cookies?

Essential cookies are necessary for the website to function properly.

Can users opt-out of essential cookies?

Opt-out rights do not apply to essential cookies.

Last updated: Sep 4, 2024